Pharmalittle: Califf admits Alzheimer’s drug controversy has hurt expert trust in FDA; House passes bill to lower insulin costs
[ad_1] And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, is exceedingly modest. We plan to catch up on our reading, take a few naps, have a listening party with…